Do analysts recommend NMTR or XRTX?

Given 9 Meters Biopharma's higher possible upside, equities research analysts clearly believe 9 Meters Biopharma is more favorable than XORTX Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, NMTR or XRTX?

XORTX Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 9 Meters Biopharma N/A N/A -$43.77M -$3.46 N/A XORTX Therapeutics N/A N/A -$2.66M -$2.63 N/A

Is NMTR or XRTX more profitable?

XORTX Therapeutics' return on equity of -150.01% beat 9 Meters Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets 9 Meters Biopharma N/A -584.97% -159.45% XORTX Therapeutics N/A -150.01% -106.53%

Do analysts recommend NMTR or SILO?

Given 9 Meters Biopharma's higher probable upside, equities research analysts clearly believe 9 Meters Biopharma is more favorable than Silo Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend SPRC or NMTR?

Given 9 Meters Biopharma's higher possible upside, analysts clearly believe 9 Meters Biopharma is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, SPRC or NMTR?

SciSparc has higher revenue and earnings than 9 Meters Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $856K 4.36 -$12.18M N/A N/A 9 Meters Biopharma N/A N/A -$43.77M -$3.46 N/A

Is SPRC or NMTR more profitable?

SciSparc's return on equity of 0.00% beat 9 Meters Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A 9 Meters Biopharma N/A -584.97% -159.45%

Do analysts rate MBRX or NMTR?

Moleculin Biotech currently has a consensus target price of $22.00, suggesting a potential upside of 3,506.56%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than 9 Meters Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, MBRX or NMTR?

Moleculin Biotech is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moleculin Biotech N/A N/A -$33.56M -$17.98 N/A 9 Meters Biopharma N/A N/A -$43.77M -$3.46 N/A

Is MBRX or NMTR more profitable?

9 Meters Biopharma's return on equity of -584.97% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A -1,422.36% -70.62% 9 Meters Biopharma N/A -584.97% -159.45%

Do analysts rate GLMD or NMTR?

Given 9 Meters Biopharma's higher probable upside, analysts clearly believe 9 Meters Biopharma is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, GLMD or NMTR?

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galmed Pharmaceuticals N/A N/A -$10.31M -$0.91 N/A 9 Meters Biopharma N/A N/A -$43.77M -$3.46 N/A

Is GLMD or NMTR more profitable?

Galmed Pharmaceuticals' return on equity of -35.32% beat 9 Meters Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -35.32% -30.94% 9 Meters Biopharma N/A -584.97% -159.45%

9 Meters Biopharma (NMTR) Competitors

Compare

NMTR vs. XRTX, SILO, SPRC, MBRX, and GLMD

Should you buy 9 Meters Biopharma stock or one of its competitors? 9 Meters Biopharma's main competitors and comparable companies include XORTX Therapeutics (XRTX), Silo Pharma (SILO), SciSparc (SPRC), Moleculin Biotech (MBRX), and Galmed Pharmaceuticals (GLMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does 9 Meters Biopharma compare to XORTX Therapeutics?

9 Meters Biopharma (NASDAQ:NMTR) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Given 9 Meters Biopharma's higher possible upside, equities research analysts clearly believe 9 Meters Biopharma is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

XORTX Therapeutics' return on equity of -150.01% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
9 Meters Biopharma	N/A	-584.97%	-159.45%
XORTX Therapeutics	N/A	-150.01%	-106.53%

In the previous week, XORTX Therapeutics had 3 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 3 mentions for XORTX Therapeutics and 0 mentions for 9 Meters Biopharma. XORTX Therapeutics' average media sentiment score of 1.08 beat 9 Meters Biopharma's score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
9 Meters Biopharma	Neutral
XORTX Therapeutics	Positive

22.3% of 9 Meters Biopharma shares are owned by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are owned by institutional investors. 2.4% of 9 Meters Biopharma shares are owned by company insiders. Comparatively, 6.9% of XORTX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

XORTX Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.63	N/A

Summary

XORTX Therapeutics beats 9 Meters Biopharma on 8 of the 12 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Silo Pharma?

9 Meters Biopharma (NASDAQ:NMTR) and Silo Pharma (NASDAQ:SILO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

9 Meters Biopharma has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Silo Pharma has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market.

Given 9 Meters Biopharma's higher probable upside, equities research analysts clearly believe 9 Meters Biopharma is more favorable than Silo Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

22.3% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 5.6% of Silo Pharma shares are held by institutional investors. 2.4% of 9 Meters Biopharma shares are held by insiders. Comparatively, 3.6% of Silo Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Silo Pharma had 4 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 4 mentions for Silo Pharma and 0 mentions for 9 Meters Biopharma. Silo Pharma's average media sentiment score of 0.47 beat 9 Meters Biopharma's score of 0.00 indicating that Silo Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
9 Meters Biopharma	Neutral
Silo Pharma	Neutral

9 Meters Biopharma has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -78.94% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
9 Meters Biopharma	N/A	-584.97%	-159.45%
Silo Pharma	-6,726.39%	-78.94%	-63.86%

Silo Pharma has higher revenue and earnings than 9 Meters Biopharma. Silo Pharma is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A
Silo Pharma	$72.10K	55.61	-$4.23M	-$4.36	N/A

Summary

Silo Pharma beats 9 Meters Biopharma on 8 of the 14 factors compared between the two stocks.

How does 9 Meters Biopharma compare to SciSparc?

SciSparc (NASDAQ:SPRC) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

SciSparc has higher revenue and earnings than 9 Meters Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$856K	4.36	-$12.18M	N/A	N/A
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

25.1% of SciSparc shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 1.5% of SciSparc shares are owned by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Given 9 Meters Biopharma's higher possible upside, analysts clearly believe 9 Meters Biopharma is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

SciSparc has a beta of 2.78, suggesting that its share price is 178% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

In the previous week, SciSparc had 7 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 7 mentions for SciSparc and 0 mentions for 9 Meters Biopharma. SciSparc's average media sentiment score of 0.68 beat 9 Meters Biopharma's score of 0.00 indicating that SciSparc is being referred to more favorably in the media.

Company	Overall Sentiment
SciSparc	Positive
9 Meters Biopharma	Neutral

SciSparc's return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
9 Meters Biopharma	N/A	-584.97%	-159.45%

Summary

SciSparc beats 9 Meters Biopharma on 9 of the 11 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Moleculin Biotech?

Moleculin Biotech (NASDAQ:MBRX) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

9 Meters Biopharma's return on equity of -584.97% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-1,422.36%	-70.62%
9 Meters Biopharma	N/A	-584.97%	-159.45%

Moleculin Biotech is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

Moleculin Biotech has a beta of 1.83, meaning that its share price is 83% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

In the previous week, Moleculin Biotech had 7 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 7 mentions for Moleculin Biotech and 0 mentions for 9 Meters Biopharma. Moleculin Biotech's average media sentiment score of 0.56 beat 9 Meters Biopharma's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Moleculin Biotech	Positive
9 Meters Biopharma	Neutral

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 1.1% of Moleculin Biotech shares are owned by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Moleculin Biotech currently has a consensus target price of $22.00, suggesting a potential upside of 3,506.56%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than 9 Meters Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Moleculin Biotech beats 9 Meters Biopharma on 8 of the 13 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Galmed Pharmaceuticals?

Galmed Pharmaceuticals (NASDAQ:GLMD) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$0.91	N/A
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 0 mentions for 9 Meters Biopharma. Galmed Pharmaceuticals' average media sentiment score of 0.30 beat 9 Meters Biopharma's score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Galmed Pharmaceuticals	Neutral
9 Meters Biopharma	Neutral

Given 9 Meters Biopharma's higher probable upside, analysts clearly believe 9 Meters Biopharma is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Galmed Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

Galmed Pharmaceuticals' return on equity of -35.32% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%
9 Meters Biopharma	N/A	-584.97%	-159.45%

Summary

Galmed Pharmaceuticals beats 9 Meters Biopharma on 9 of the 12 factors compared between the two stocks.

Get 9 Meters Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMTR vs. The Competition

Export

Metric	9 Meters Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.04M	$11.80B	$7.03B	$13.07B
Dividend Yield	N/A	2.70%	2.57%	10.65%
P/E Ratio	0.00	779.99	271.26	25.37
Price / Sales	N/A	748.85	622.96	106.04
Price / Cash	N/A	89.04	75.70	53.27
Price / Book	N/A	11.60	12.92	6.21
Net Income	-$43.77M	$2.77B	$3.45B	$347.71M

9 Meters Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	$1.04M	N/A	N/A	20
XRTX XORTX Therapeutics	0.9138 of 5 stars	$2.19 +1.4%	N/A	-51.2%	$3.93M	N/A	N/A	N/A	Earnings Report Gap Up
SILO Silo Pharma	0.5629 of 5 stars	$3.22 +3.9%	N/A	-70.0%	$3.88M	$70K	N/A	2	Positive News Earnings Report
SPRC SciSparc	0.5621 of 5 stars	$6.69 +1.4%	N/A	-83.8%	$3.73M	$860K	N/A	4	Short Interest Increase
MBRX Moleculin Biotech	2.2569 of 5 stars	$0.57 +9.4%	$22.00 +3,750.9%	-96.4%	$3.71M	N/A	N/A	20	News Coverage Earnings Report Analyst Upgrade Short Interest Increase Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMTR) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

9 Meters Biopharma (NMTR) Competitors

NMTR vs. XRTX, SILO, SPRC, MBRX, and GLMD

How does 9 Meters Biopharma compare to XORTX Therapeutics?

Summary

How does 9 Meters Biopharma compare to Silo Pharma?

Summary

How does 9 Meters Biopharma compare to SciSparc?

Summary

How does 9 Meters Biopharma compare to Moleculin Biotech?

Summary

How does 9 Meters Biopharma compare to Galmed Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTR vs. The Competition

9 Meters Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

9 Meters Biopharma (NMTR) Competitors

NMTR vs. XRTX, SILO, SPRC, MBRX, and GLMD

How does 9 Meters Biopharma compare to XORTX Therapeutics?

Which has more risk and volatility, NMTR or XRTX?

Do analysts recommend NMTR or XRTX?

Is NMTR or XRTX more profitable?

Does the media prefer NMTR or XRTX?

Do insiders & institutionals hold more shares of NMTR or XRTX?

Which has higher earnings & valuation, NMTR or XRTX?

Summary

How does 9 Meters Biopharma compare to Silo Pharma?

Which has more volatility & risk, NMTR or SILO?

Do analysts recommend NMTR or SILO?

Do insiders & institutionals hold more shares of NMTR or SILO?

Does the media refer more to NMTR or SILO?

Is NMTR or SILO more profitable?

Which has preferable earnings and valuation, NMTR or SILO?

Summary

How does 9 Meters Biopharma compare to SciSparc?

Which has better earnings & valuation, SPRC or NMTR?

Do institutionals & insiders believe in SPRC or NMTR?

Do analysts recommend SPRC or NMTR?

Which has more volatility & risk, SPRC or NMTR?

Does the media prefer SPRC or NMTR?

Is SPRC or NMTR more profitable?

Summary

How does 9 Meters Biopharma compare to Moleculin Biotech?

Is MBRX or NMTR more profitable?

Which has better earnings and valuation, MBRX or NMTR?

Which has more volatility & risk, MBRX or NMTR?

Does the media prefer MBRX or NMTR?

Do institutionals and insiders have more ownership in MBRX or NMTR?

Do analysts rate MBRX or NMTR?

Summary

How does 9 Meters Biopharma compare to Galmed Pharmaceuticals?

Which has higher valuation and earnings, GLMD or NMTR?

Do institutionals & insiders have more ownership in GLMD or NMTR?

Does the media prefer GLMD or NMTR?

Do analysts rate GLMD or NMTR?

Which has more risk and volatility, GLMD or NMTR?

Is GLMD or NMTR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTR vs. The Competition

9 Meters Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools